Rapid in vivo testing of drug response in multiple myeloma made possible by xenograft to turkey embryos

British Journal of Cancer

Volumn 105, Issue 11, 2011, Pages 1708-1718

  Farnoushi, Y ^a,b   Cipok, M ^a   Kay, S ^a   Jan, H ^a,b   Ohana, A ^b   Naparstek, E ^a   Goldstein, R S ^b   Deutsch, V R ^a  

^a TEL AVIV UNIVERSITY   (Israel)

^b BAR ILAN UNIVERSITY   (Israel)

Author keywords

drug response; multiple myeloma; turkey embryo xenograft

Indexed keywords

BORTEZOMIB; IMMUNOGLOBULIN LIGHT CHAIN; LENALIDOMIDE;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; EMBRYO; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MULTIPLE MYELOMA; NONHUMAN; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; TUMOR ENGRAFTMENT; TUMOR XENOGRAFT; TURKEY (BIRD);

ANIMALS; ANTINEOPLASTIC AGENTS; BONE MARROW; BORONIC ACIDS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; EMBRYO, NONMAMMALIAN; FLOW CYTOMETRY; HUMANS; MULTIPLE MYELOMA; NEOPLASM TRANSPLANTATION; PYRAZINES; REAL-TIME POLYMERASE CHAIN REACTION; TURKEYS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 81955165194     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2011.445     Document Type: Article

References (31)

1. Borset M, Hjertner O, Yaccoby S, Epstein J, Sanderson RD (2000) Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. Blood 96: 2528-2536
2. Boulland JL, Halasi G, Kasumacic N, Glover JC (2010) Xenotransplantation of human stem cells into the chicken embryo. J Vis Exp (41): pii 2071, doi:10.3791/2071
3. Chauhan D, Singh AV, Aujay M, Kirk CJ, Bandi M, Ciccarelli B, Raje N, Richardson P, Anderson KC (2010) A novel orally active proteasome inhibitor ONX 0912 triggers in vitro and in vivo cytotoxicity in multiple myeloma. Blood 116: 4906-4915
4. Dalloul RA, Long JA, Zimin AV, Aslam L, Beal K, Ann Blomberg L, Bouffard P, Burt DW, Crasta O, Crooijmans RP, Cooper K, Coulombe RA, De S, Delany ME, Dodgson JB, Dong JJ, Evans C, Frederickson KM, Flicek P, Florea L, Folkerts O, Groenen MA, Harkins TT, Herrero J, Hoffmann S, Megens HJ, Jiang A, de Jong P, Kaiser P, Kim H, Kim KW, Kim S, Langenberger D, Lee MK, Lee T, Mane S, Marcais G, Marz M, McElroy AP, Modise T, Nefedov M, Notredame C, Paton IR, Payne WS, Pertea G, Prickett D, Puiu D, Qioa D, Raineri E, Ruffier M, Salzberg SL, Schatz MC, Scheuring C, Schmidt CJ, Schroeder S, Searle SM, Smith EJ, Smith J, Sonstegard TS, Stadler PF, Tafer H, Tu ZJ, Van Tassell CP, Vilella AJ, Williams KP, Yorke JA, Zhang L, Zhang HB, Zhang X, Zhang Y, Reed KM (2011) Multi-platform next-generation sequencing of the domestic turkey (Meleagris gallopavo): genome assembly and analysis. PLoS Biol 8: pii: e1000475
5. Dazzi F, Hasserjian R, Gordon MY, Boecklin F, Cotter F, Corbo M, Capelli D, Goldman JM (2000) Normal and chronic phase CML hematopoietic cells repopulate NOD/SCID bone marrow with different kinetics and cell lineage representation. Hematol J 1: 307-315
6. Dispenzieri A, Kyle R, Merlini G, Miguel JS, Ludwig H, Hajek R, Palumbo A, Jagannath S, Blade J, Lonial S, Dimopoulos M, Comenzo R, Einsele H, Barlogie B, Anderson K, Gertz M, Harousseau JL, Attal M, Tosi P, Sonneveld P, Boccadoro M, Morgan G, Richardson P, Sezer O, Mateos MV, Cavo M, Joshua D, Turesson I, Chen W, Shimizu K, Powles R, Rajkumar SV, Durie BG (2009) International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders. Leukemia 23: 215-224
7. Feo-Zuppardi FJ, Taylor CW, Iwato K, Lopez MH, Grogan TM, Odeleye A, Hersh EM, Salmon SE (1992) Long-term engraftment of fresh human myeloma cells in SCID mice. Blood 80: 2843-2850
8. Feuring-Buske M, Gerhard B, Cashman J, Humphries RK, Eaves CJ, Hogge DE (2003) Improved engraftment of human acute myeloid leukemia progenitor cells in beta 2-microglobulin-deficient NOD/SCID mice and in NOD/SCID mice transgenic for human growth factors. Leukemia 17: 760-763 (Pubitemid 36519373)
9. Ghosh N, Ye X, Ferguson A, Huff CA, Borrello I (2011) Bortezomib and thalidomide, a steroid free regimen in newly diagnosed patients with multiple myeloma. Br J Haematol 152: 593-599
10. Grinberg I, Reis A, Ohana A, Taizi M, Cipok M, Tavor S, Rund D, Deutsch VR, Goldstein RS (2009) Engraftment of human blood malignancies to the turkey embryo: a robust new in vivo model. Leuk Res 33: 1417-1426
11. Ito T, Ando H, Suzuki T, Ogura T, Hotta K, Imamura Y, Yamaguchi Y, Handa H (2010) Identification of a primary target of thalidomide teratogenicity. Science 327: 1345-1350
12. Kobayashi T, Koshida K, Endo Y, Imao T, Uchibayashi T, Sasaki T, Namiki M (1998) A chick embryo model for metastatic human prostate cancer. Eur Urol 34: 154-160 (Pubitemid 28398467)
13. Koop S, MacDonald IC, Luzzi K, Schmidt EE, Morris VL, Grattan M, Khokha R, Chambers AF, Groom AC (1995) Fate of melanoma cells entering the microcirculation: over 80% survive and extravasate. Cancer Res 55: 2520-2523
14. Kumar A, Hozo I, Wheatley K, Djulbegovic B (2011) Thalidomide versus bortezomib based regimens as first-line therapy for patients with multiple myeloma: a systematic review. Am J Hematol 86: 18-24
15. Leupin N, Kuhn A, Hugli B, Grob TJ, Jaggi R, Tobler A, Delorenzi M, Fey MF (2006) Gene expression profiling reveals consistent differences between clinical samples of human leukaemias and their model cell lines. Br J Haematol 135: 520-523 (Pubitemid 44583418)
16. Li M, Chen F, Clifton N, Sullivan DM, Dalton WS, Gabrilovich DI, Nefedova Y (2011) Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect. Mol Cancer Ther 9: 3200-3209
17. Lock RB, Liem N, Farnsworth ML, Milross CG, Xue C, Tajbakhsh M, Haber M, Norris MD, Marshall GM, Rice AM (2002) The nonobese diabetic/severe combined immunodeficient (NOD/SCID) mouse model of childhood acute lymphoblastic leukemia reveals intrinsic differences in biologic characteristics at diagnosis and relapse. Blood 99: 4100-4108 (Pubitemid 35332053)
18. Melchert M, List A (2007) The thalidomide saga. Int J Biochem Cell Biol 39: 1489-1499 (Pubitemid 47031027)
19. Nefedova Y, Sullivan DM, Bolick SC, Dalton WS, Gabrilovich DI (2008) Inhibition of Notch signaling induces apoptosis of myeloma cells and enhances sensitivity to chemotherapy. Blood 111: 2220-2229 (Pubitemid 351451536)
20. Palumbo A (2010) First-line treatment of elderly multiple myeloma patients. Clin Adv Hematol Oncol 8: 529-530
21. Pearce DJ, Taussig D, Zibara K, Smith LL, Ridler CM, Preudhomme C, Young BD, Rohatiner AZ, Lister TA, Bonnet D (2006) AML engraftment in the NOD/SCID assay reflects the outcome of AML: implications for our understanding of the heterogeneity of AML. Blood 107: 1166-1173 (Pubitemid 43156319)
22. Peled A, Hardan I, Trakhtenbrot L, Gur E, Magid M, Darash-Yahana M, Cohen N, Grabovsky V, Franitza S, Kollet O, Lider O, Alon R, Rechavi G, Lapidot T (2002) Immature leukemic CD34+CXCR4+ cells from CML patients have lower integrin-dependent migration and adhesion in response to the chemokine SDF-1. Stem Cells 20: 259-266 (Pubitemid 34507442)
23. Rebbaa A, Chu F, Sudha T, Gallati C, Dier U, Dyskin E, Yalcin M, Bianchini C, Shaker O, Mousa SA (2009) The anti-angiogenic activity of NSITC, a specific cathepsin L inhibitor. Anticancer Res 29: 4473-4481
24. Ribatti D, Nico B, Pezzolo A, Vacca A, Meazza R, Cinti R, Carlini B, Parodi F, Pistoia V, Corrias MV (2006) Angiogenesis in a human neuroblastoma xenograft model: mechanisms and inhibition by tumour-derived interferon-gamma. Br J Cancer 94: 1845-1852 (Pubitemid 43882575)
25. Richardson P, Mitsiades C, Laubach J, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson K (2010) Lenalidomide in multiple myeloma: an evidence-based review of its role in therapy. Core Evid 4: 215-245
26. Taizi M, Deutsch VR, Leitner A, Ohana A, Goldstein RS (2006) A novel and rapid in vivo system for testing therapeutics on human leukemias. Exp Hematol 34: 1698-1708 (Pubitemid 44838998)
27. Tassone P, Neri P, Carrasco DR, Burger R, Goldmacher VS, Fram R, Munshi V, Shammas MA, Catley L, Jacob GS, Venuta S, Anderson KC, Munshi NC (2005) A clinically relevant SCID-hu in vivo model of human multiple myeloma. Blood 106: 713-716 (Pubitemid 40981270)
28. Wunderlich M, Chou FS, Link KA, Mizukawa B, Perry RL, Carroll M, Mulloy JC (2010) AML xenograft efficiency is significantly improved in NOD/SCID-IL2RG mice constitutively expressing human SCF, GM-CSF and IL-3. Leukemia 24: 1785-1788
29. Yaccoby S, Barlogie B, Epstein J (1998) Primary myeloma cells growing in SCID-hu mice: a model for studying the biology and treatment of myeloma and its manifestations. Blood 92: 2908-2913 (Pubitemid 28469106)
30. Yagami K, Suh JY, Enomoto-Iwamoto M, Koyama E, Abrams WR, Shapiro IM, Pacifici M, Iwamoto M (1999) Matrix GLA protein is a developmental regulator of chondrocyte mineralization and, when constitutively expressed, blocks endochondral and intramembranous ossification in the limb. J Cell Biol 147: 1097-1108
31. Zhang QL, Wang L, Zhang YW, Jiang XX, Yang F, Wu WL, Janin A, Chen Z, Shen ZX, Chen SJ, Zhao WL (2009) The proteasome inhibitor bortezomib interacts synergistically with the histone deacetylase inhibitor suberoylanilide hydroxamic acid to induce T-leukemia/lymphoma cells apoptosis. Leukemia 23: 1507-1514